Why Norivar exists
Norivar was created because early-stage research and anecdotal reports about ibogaine generate public interest faster than peer-reviewed synthesis and regulatory guidance can keep up. Our mission is plain: provide an independent resource on ibogaine and noribogaine research in opioid use disorder that helps people distinguish early findings, established care options, and serious safety limitations.
Our editorial approach
We describe the categories of information we curate, how content is sourced, and how we flag uncertainty. Our editorial process emphasizes primary literature, clinical trial registries, and official regulatory notices, and we cross-check claims with authoritative sources where available. For example, when summarizing trial status we consult registered trial listings and when noting safety signals we refer to official advisories or peer-reviewed case series; this is consistent with accepted evidence-synthesis practices found on encyclopedic resources such as Wikipedia's summary of evidence-based medicine.
What we cover
We cover the research landscape, methods used in studies, how findings are interpreted, and the limitations of the evidence. Content is organized by topic pages, explanatory overviews, safety-focused analyses, and a services index for people seeking established treatment options. If you are exploring options, our services index offers contextual listings and links to care pathways; see the entry on services and vetted care pathways for how we present that information.
How information is sourced and vetted
We prioritize primary sources (peer-reviewed journals, registered clinical trials), public health communications (for example, guidance from U.S. agencies and other regulators), and university-hosted research summaries. When relevant, we link to official registries and to clinical trial entries to show status and methods; registries such as ClinicalTrials.gov are commonly used to verify trial details and enrollment status ClinicalTrials.gov. Our editorial notes make explicit whether a claim is supported by controlled trials, observational reports, or early-phase research.
Who this is for
This resource is written for people affected by opioid use, their families, researchers, and policymakers seeking calm, evidence-first context. It is not a substitute for medical advice; readers should consult licensed healthcare providers about individual treatment decisions.
Editorial principles
- Independence — we avoid financial ties that could bias summaries.
- Evidence before hype — we distinguish preliminary results from replicated findings.
- Risk clarity — we document known safety limitations plainly and early in each relevant piece.
- Plain language — technical topics are translated for non-specialist readers without oversimplifying uncertainty.
- Respect for established care — we situate experimental findings relative to licensed treatment options.
To explore the site from the starting point we use for navigation and topic framing, follow an entry back to the main overview where major topics are connected; the homepage contains that orientation and links into our topic hubs at the top level of the site via the site index linked from the front page (site overview and index).
